Keyword
in
Collection
Date
to
Download Folder

0 items

Houston Voice, June 25, 2004
File 020
Citation
MLA
APA
Chicago/Turabian
Houston Voice, June 25, 2004 - File 020. 2004-06-25. University of Houston Libraries. University of Houston Digital Library. Web. December 15, 2017. http://digital.lib.uh.edu/collection/montrose/item/7279/show/7249.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2004-06-25). Houston Voice, June 25, 2004 - File 020. Montrose Voice. University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/montrose/item/7279/show/7249

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, June 25, 2004 - File 020, 2004-06-25, Montrose Voice, University of Houston Libraries, accessed December 15, 2017, http://digital.lib.uh.edu/collection/montrose/item/7279/show/7249.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, June 25, 2004
Contributor
  • Crain, Chris
  • Fisher, Binnie
Publisher Window Media
Date June 25, 2004
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Rights In Copyright: This item is protected by copyright. Copyright to this resource is held by the creator or current rights holder, and the resource is provided here for educational purposes. It may not be reproduced or distributed in any format without permission of the copyright owner. Users assume full responsibility for any infringement of copyright or related rights.
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 020
Transcript HOUSTON VOICE www.houstonvoice.com JUNE 25, 2004 19 _____% Seftle So keep undetectable as your treatment goal, even If previous regimens have failed you. To find out more about FUZEON and how it works, visit www.FUZEON.com or call the FUZEON Answer Center at 1-877-4 FUZEON (1-877-438-9366). If you are treatment experienced, with FUZEON in your regimen sou ma> still get to undetectable. In fact, compared to HIV treatment regihiens without FUZEON, having FUZEON in your combination regimen means you may: • be twice as likely to get to undetectable and • get twtee the increase In T cells FUZEON fights HIV In a completely different way. It's the only anti-HIV medicine that works outside the T cell to block HIV from getting Inside and Infecting healthy cells. So fell your doctor you donf want to iccept a detectable viral load. Jell your doctor you re ready to fight in a completely different way—with FUZEON. •5- FUZEDn. • enfuvirtide Indication: FUZEON (enfuvirtide) is used with other anti-HIV medicines to treat HIV-1 infection in patients who have taken anti-HIV medicines (treatment-experienced) and have detectable viral loads even though they are taking anti-HIV medicines. This indication is based on viral loads and CD4 (T-cell) counts in studies of FUZEON that lasted 24 weeks. Patients in the studies were treatment-experienced adults, and many of them had advanced HIV disease. There are no studies of FUZEON in patients who haven't taken anti-HIV medicines. There are no results from studies looking at the effect of FUZEON on the progression of HIV disease. Important Safety Information Injection Site Reactions (ISRs): ISRs are the most common side effect seen with FUZEON use. Almost all people taking FUZEON (98%) get injection site reactions. 3% of patients quit taking FUZEON because of ISRs. Reactions are usually mild to moderate but occasionally may be severe. Signs/symptoms may include pain and discomfort, hardened skin, redness, bumps, itching and swelling. 9% of patients had ISRs that required them to take over-the-counter pain medicine or limit their usual activities. Pneumonia: Patients taking FUZEON with other anti-HIV medicines got bacterial pneumonia more often than patients not taking FUZEON. It is unclear if this was related to trie use of FUZEON. You should contact your healthcare provider right away if you have a cough, fever or trouble breathing. Patients are more likely to get bacterial pneumonia if they have a low number of CD4 cells, have a high viral load, use intravenous (injected into the vein) drugs, smoke or have had lung disease in the past Allergic reactions: Allergic reactions have been seen with FUZEON and can occur if FUZEON is restarted. Symptoms of a serious allergic reaction with FUZEON can include rash, fever, nausea and vomiting, chills, shaking, low blood pressure and increased liver enzymes. Other adverse events that may be an immune response and have been reported in patients taking FUZEON include serious immune system reactions, severe breathing difficulties, inflammation of the kidney and Guillain-Barre syndrome. Other Side Effects: The side effects seen most often in patents taking FUZEON with their other anti-HIV medicines were diarrhea (26.8%), nausea (20.1%) and fatigue (16.1%). These side effects were seen less often than in patients taking anti-HIV medicines without FUZEON: diarrhea (33.5%), nausea (23.7%) and fatigue (17.4%). This list of side effects is not complete because FUZEON is still being studied. W If you have questions about side effects, ask your healthcare provider. Report any new or worsening symptoms to your healthcare provider. FUZEON* is not a cure fot HIV infection or AIDS. FUZEON does not prevent the transmission of HIV. For additional details on FUZEON, please see the accompanying summary of complete product information. Copyright © 2004 Roche Laboratories Inc. and Trimeris, Inc. All nghts reserved. 85-090-118-013-0704
File Name uhlib_31485329_n1235_019.jpg